| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |